Drugs / Imzokitug
Imzokitug
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04895709 | May 2021 → Aug 2031 expected | cervical cancer, colorectal cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma +7 | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07680764 | Aug 2026 → Sep 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07226856 | Dec 2025 → Dec 2028 expected | pancreatic adenocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT07011550 | Aug 2025 → Jul 2028 | colorectal cancer | M.D. Anderson Cancer Center | Suspended | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imzokitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226856 ↗ |
| Known as | Anti-CCR8 mAb | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068454 ↗ |
| Known as | BMS-986340 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895709 ↗ |
| Known as | CCR8.50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068454 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068454 ↗ |
| Route | Intravenous | “Given by IV” NCT07011550 ↗ |